UBS has increased its price target for CVS Health from $115 to $122, indicating a potential 13.12% upside based on the stock's recent price of $107.85. CVS Health has outperformed the S&P 500 and its industry peers, boosted by its expansion into pet prescription services across 9,000 pharmacies. The company is expected to report higher earnings and revenue in its upcoming August 5 earnings report, reflecting positive growth prospects. This upgrade highlights investor confidence in CVS's market position and future earnings potential.
CVS Health has invested over $83 million to create and renovate more than 3,500 affordable housing units across Massachusetts, supporting families, older adults, and individuals. The company also partners with nonprofits like Community Servings to pr...
CVS Health has expanded its pharmacy services to include common prescription medications for dogs and cats at all its approximately 9,000 CVS Pharmacy locations across the U.S. This new service allows pet owners to conveniently fill prescriptions for...
